We are a global, clinical stage pharmaceutical company with a mission to develop and commercialise clinically meaningful, novel therapeutics that will bring life-enhancing benefits to children across the world.

Our first development program focuses on Hu14.18, a humanised anti-GD2 monoclonal antibody, licensed from St. Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma.

A novel key Phase II trial incorporated the addition of Hu14.18 antibody to standard induction chemotherapy and demonstrated outstanding outcomes in patients with newly diagnosed high-risk neuroblastoma, with a 3-year event-free (EFS) and overall survival (OS) of 73.7% and 86.0% respectively.

Renaissance Pharma Ltd is led by an Executive Team with extensive experience in the development, approval and commercialisation of oncology and rare disease products.

We invite industry manufacturers, formulators, researchers and investors to collaborate with us. Together we can build new partnerships to improve patients' lives. To discuss partnership opportunities, please contact info@renaissancepharma.co.uk

Renaissance Pharma Ltd

Org chart

Teams

Offices